骨髄異形成症候群(MDS)治療薬の世界市場:治療クラス別(DNAメチル化阻害薬、免疫調節薬、抗貧血薬)、セグメント予測

【英語タイトル】Myelodysplastic Syndrome (MDS) Drugs Market Size, Share & Trends Analysis By Therapeutic Class (Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics), And Segment Forecasts, 2016 - 2022

Grand View Researchが出版した調査資料(GVW8NV134)・商品コード:GVW8NV134
・発行会社(調査会社):Grand View Research
・発行日:2018年8月
・ページ数:67
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:Pharmaceuticals
◆販売価格オプション(消費税別)
Single UserUSD4,450 ⇒換算¥658,600見積依頼/購入/質問フォーム
Multi UserUSD6,450 ⇒換算¥954,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,450 ⇒換算¥1,250,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
骨髄異形成症候群(MDS)治療薬の世界市場は2022年には24億米ドルに達し、予測期間中、年平均成長率9.7%で成長すると予測されています。この市場の成長を促す要因として、強力な製品パイプライン、高齢者人口の増加、この市場に有利な政府の取り組みなどが考えられます。本調査レポートでは、骨髄異形成症候群(MDS)治療薬の世界市場について調査・分析し、骨髄異形成症候群(MDS)治療薬の世界市場動向、骨髄異形成症候群(MDS)治療薬の世界市場規模、市場予測、セグメント別骨髄異形成症候群(MDS)治療薬市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global myelodysplastic syndrome (MDS) drugs market size is expected to reach USD 2.4 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a 9.7% CAGR during the forecast period. Factors such as strong product pipeline, rising geriatric population, and favorable government initiatives are driving the market.
MDS is caused by mutation of one or more genes that control development of blood cells. Patients with this condition may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Although majority of cases (over 90%) are reported in people over the age of 60, the condition can occur at any age, more frequently in men than in women. About 30% of MDS cases advance to acute myeloid leukemia (AML).

The immunomodulatory drug segment is expected to retain its dominant position in the MDS drugs market due to strong sales of Revlimid. Supported by potential approvals of luspatercept and Aranesp, the anti-anemics drug segment is forecast to gain higher market share than hypomethylating agents, thus contributing significantly to the overall expansion of the market.

Developing novel drugs for the treatment of rare subsets of MDS patients is a key challenge as the disease is highly heterogeneous at the molecular level. In addition, morbidity issues and poor quality of life due to incapacitating effects of the standard of care treatment paradigms are causes of inconvenience for geriatric population.

Further key findings from the report suggest:

• An estimated 60,000 people in U.S. are living with myelodysplastic syndrome, with approximately 10,000-15,000 new cases being reported annually

• U.S. dominated the global MDS drugs market with more than 48.0% share in 2016 owing to rising disease incidence and launch of strong pipeline candidates

• Emerging markets such as India, China, and South Korea are expected to exhibit lucrative growth during the forecast period due to favorable government policies, rising awareness about hematological malignancies, increased investment, and improved healthcare infrastructure

• Immunomodulatory drugs led the drug classes with a market share of more than 54.0% in 2016. Hypomethylating agents are projected to witness a double-digit decline in market share due to expected patent expirations

• Celgene, Amgen, Otsuka, and Takeda are some of the key players operating in this area; Celgene accounted for 95.2% of the market in 2016, driven by strong sales of Revlimid and Vidaza

• Currently, there are about 45 pipeline drugs in various stages of clinical development. Promising pipeline candidates such as Aranesp, luspatercept, Vyxeos, guadecitabine, and pevonedistat are expected to generate significant revenue upon launch.

【レポートの目次】

Table of Contents

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Types
3.1.2 Epidemiology
3.1.3 Current prevalence and incidence for seven major markets (U.S., Japan, EU5)
Chapter 4 Global Market Overview
4.1 Market by Treatment
4.1.1 Supportive Therapy
4.1.1.1 Blood transfusions
4.1.1.2 Iron chelation therapy
4.1.1.3 Growth factors
4.1.2 Chemotherapy
4.1.3 Stem cell transplantation
4.2 Market by Therapeutic Class
4.2.1 Hypomethylating agents
4.2.2 Immunomodulatory drugs
4.2.3 Anti-anemics
4.3 Market Size & Forecast
4.4 Sales Performance
4.4.1 Sales performance, by drug class (2016 – 2022)
4.4.2 Sales performance, by countries (2016 – 2022)
4.4.3 Sales performance, by company (2016 – 2022)
4.5 Market Share Distribution
4.6 Market Dynamics and Brand Strategies
4.7 Patent Expiry Schedule
4.8 Drivers and Challenges
4.9 M&A, Deal Landscape (2013-2017 YTD)
4.10 Pricing and Reimbursement
4.11 SWOT
Chapter 5 Pipeline Intelligence
5.1 Pipeline Landscape
5.1.1 Leading drugs in development
5.1.2 Key R&D trends
5.2 Promising Drug Candidates in Pipeline
5.2.1 Late stage pipeline analysis
5.2.2 Profile of disruptive drugs
5.2.2.1 Luspatercept (ACE-536)
5.2.2.2 Aranesp (Darbepoetin alfa)
5.3 Global Pipeline Forecast
Chapter 6 Competitive Landscape
6.1 Celgene
6.1.1 Company overview
6.1.2 Current product portfolio-Major products
6.1.3 Product forecast sales up to 2022
6.1.4 Strategic initiatives (Celgene)
6.1.4.1 Key company news flow
6.1.5 Pipeline overview
6.1.6 SWOT
6.2 Amgen
6.2.1 Company overview
6.2.2 Current product portfolio-Major products
6.2.3 Product forecast sales up to 2022
6.2.4 Strategic initiatives (Amgen)
6.2.4.1 Key company news flow
6.2.5 Pipeline analysis & overview
6.2.6 SWOT
6.3 Otsuka
6.3.1 Company overview
6.3.2 Current product portfolio-Major products
6.3.3 Product forecast sales up to 2022
6.3.4 Strategic initiatives (Otsuka)
6.3.4.1 Key company news flow
6.3.5 Pipeline analysis & overview
6.3.6 SWOT
6.4 Takeda
6.4.1 Company overview
6.4.2 Current roduct portfolio-Major products
6.4.3 Product forecast sales up to 2022
6.4.4 Strategic initiatives (Takeda)
6.4.4.1 Key company news flow
6.4.5 Pipeline analysis & overview
6.4.6 SWOT
Chapter 7 Market Outlook
7.1 What the future holds
7.2 Winners and losers
7.3 Emerging companies
7.4 The road ahead

List of Tables

TABLE 1 Sales Performance, by Drug Class (in $ million)
TABLE 2 Sales Performance, by Countries (in $ million)
TABLE 3 Sales Performance, by Company (in $ million)
TABLE 4 Patent Expiry Schedule
TABLE 5 R&D Pipeline Overview
TABLE 6 Late Stage Pipeline
TABLE 7 Product Profile: Luspatercept (ACE-536)
TABLE 8 Product Profile: Aranesp (Darbepoetin alfa)
TABLE 9 Global Pipeline Forecast
TABLE 10 Product Portfolio: Vidaza
TABLE 11 Product Portfolio: Revlimid
TABLE 12 Product Portfolio: Luspatercept
TABLE 13 Vidaza Sales Forecast, 2016 - 2022 (in $ million)
TABLE 14 Revlimid Sales Forecast, 2016 - 2022 (in $ million)
TABLE 15 Luspatercept Sales Forecast, 2016 - 2022 (in $ million)
TABLE 16 Pipeline (Celgene)
TABLE 17 Product Portfolio: Aranesp
TABLE 18 Aranesp Sales Forecast, 2016 - 2022 (in $ million)
TABLE 19 Pipeline (Amgen)
TABLE 20 Product Portfolio: Dacogen
TABLE 21 Product Portfolio: Guadecitabine
TABLE 22 Guadecitabine Sales Forecast, 2016 - 2022 (in $ million)
TABLE 23 Pipeline (Otsuka)
TABLE 24 Product Portfolio: Pevonedistat
TABLE 25 Pevonedistat Sales Forecast, 2016 - 2022 (in $ million)
TABLE 26 Pipeline (Takeda)

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 MDS Age-Adjusted Incidence Rates, per 100,000 Population, by Race - 2014
FIG. 8 MDS Age-Adjusted Incidence Rates, per 100,000 Population, by Age - 2014
FIG. 9 Myelodysplastic Syndrome Drugs Market by Therapeutic Class (2016 & 2022)
FIG. 10 Myelodysplastic Syndrome Drugs Market, $ million (2016 & 2022)
FIG. 11 Market Share Distribution (2016 & 2022)
FIG. 12 Regional Share Distribution (2016 & 2022)
FIG. 13 Myelodysplastic Syndrome Drugs Market SWOT
FIG. 14 SWOT Analysis (Celgene)
FIG. 15 SWOT Analysis (Amgen)
FIG. 16 SWOT Analysis (Otsuka)
FIG. 17 SWOT Analysis (Takeda)

【掲載企業】

Celgene
Amgen
Otsuka
Takeda

★調査レポート[骨髄異形成症候群(MDS)治療薬の世界市場:治療クラス別(DNAメチル化阻害薬、免疫調節薬、抗貧血薬)、セグメント予測] (コード:GVW8NV134)販売に関する免責事項を必ずご確認ください。
★調査レポート[骨髄異形成症候群(MDS)治療薬の世界市場:治療クラス別(DNAメチル化阻害薬、免疫調節薬、抗貧血薬)、セグメント予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆